Cargando…
Rituximab Therapy for Primary Sjögren’s Syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy,...
Autores principales: | Chen, Yi Han, Wang, Xin Yu, Jin, Xin, Yang, Zi, Xu, Jianguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445329/ https://www.ncbi.nlm.nih.gov/pubmed/34539411 http://dx.doi.org/10.3389/fphar.2021.731122 |
Ejemplares similares
-
Therapeutic effect of modified zengye decoction on primary Sjogren’s syndrome and its effect on plasma exosomal proteins
por: Zeng, Yimin, et al.
Publicado: (2022) -
Severe Headache in Primary Sjögren’s Syndrome Responded to Rituximab
por: Kudsi, Maysoun, et al.
Publicado: (2023) -
Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation
por: Quartuccio, Luca, et al.
Publicado: (2009) -
Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
por: Tjensvoll, Anne Bolette, et al.
Publicado: (2019) -
The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Wang, Xuan, et al.
Publicado: (2021)